使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning, ladies and gentlemen, and welcome to Baxter International's First Quarter 2017 Earnings Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.
各位女士、各位先生,早安,歡迎參加百特國際(Baxter International)2017 年第一季財報電話會議。(接線員指示) 提醒各位,本次電話會議由百特錄音並受著作權保護。未經百特許可,不得錄音或轉播。如有任何異議,請立即掛線。
I would now like to turn the call over to Ms. Clare Trachtman, Vice President, Investor Relations at Baxter International. Ms. Trachtman, you may begin.
現在我想把電話交給百特國際投資人關係副總裁 Clare Trachtman 女士。Trachtman 女士,請開始。
Clare Trachtman
Clare Trachtman
Thanks, Candice. Good morning, and welcome to our first quarter 2017 earnings conference call. Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; and Jay Saccaro, Baxter's Chief Financial Officer.
謝謝你,Candice。各位早安,歡迎參加我們 2017 年第一季財報電話會議。今天與我一同出席的有百特董事長兼執行長 Joe Almeida,以及百特財務長 Jay Saccaro。
On the call this morning, we will be discussing Baxter's first quarter 2017 financial results, along with our updated outlook for 2017 before taking your questions.
今天上午的電話會議中,我們將在回答各位提問之前,先討論百特 2017 年第一季財務結果,以及我們對 2017 年的最新展望。
As a reminder, we have posted a supplemental presentation to complement this morning's discussion. This presentation can be accessed on Baxter's external website in the Investors section under Events & Presentations. (Operator Instructions)
提醒各位,我們已上傳一份補充簡報,以配合今天上午的討論。該簡報可於百特對外網站的 Investors(投資人)專區,在 Events & Presentations(活動與簡報)項下取得。(接線員指示)
With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook, new product developments, business development and regulatory matters, contain forward-looking statements that involve risks and uncertainties.
接下來,我先以預先準備的發言開始,並提醒各位:本簡報(包括有關我們財務展望、新產品開發、業務發展及法規事項的評論)包含前瞻性陳述,涉及風險與不確定性。
And of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more details concerning factors that could cause actual results to differ materially.
當然,我們的實際結果可能與目前預期有重大差異。有關可能導致實際結果與預期出現重大差異的因素,請參閱今日新聞稿及我們向美國證券交易委員會(SEC)提交的文件,以取得更多細節。
In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website.
此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續營運的業務表現。今日所討論之非 GAAP 財務衡量指標與可比較之 GAAP 財務衡量指標的調節表,已包含於我們今早發布的財報新聞稿中,並可於本公司網站取得。
Now I'd like to turn the call over to Joe. Joe?
現在我想把電話交給 Joe。Joe?
José E. Almeida - Chairman, CEO and President
José E. Almeida - Chairman, CEO and President
Good morning, everyone, and thank you for joining us today. I'll get started by sharing some comments on our first quarter performance. Then I will turn it over to Jay, who will walk through the rest of the P&L and provide an update on our guidance for the year. After that, we will close with Q&A.
各位早安,感謝今天加入我們。我先分享一些關於第一季表現的評論。接著我會把時間交給 Jay,他將帶各位檢視損益表(P&L)的其餘部分,並更新我們對今年的財測指引。之後我們將進行問答。
We opened the 2017 with a strong quarter, reflecting continued progress across our 3 strategic vectors for the management and innovation, operational excellence and capital allocation. On the top line, Baxter delivered sales growth of 4% on a reported basis and 5% on a constant currency basis.
我們以強勁的一季開啟 2017 年,反映我們在三大策略主軸上持續取得進展:管理與創新、營運卓越,以及資本配置。在營收方面,百特以報告基礎計算的銷售成長 4%,以固定匯率基礎計算的銷售成長 5%。
Operationally, Baxter sales rose 7%, which excludes the impact of foreign exchange, generic competition for the U.S. cyclophosphamide market and the previously communicated selected strategic product exits the company is undertaking. The results were driven by strength across our U.S. businesses, as well as growth in peritoneal dialysis, acute renal therapies and nutrition globally.
在營運層面,百特銷售成長 7%,此數字排除外匯影響、美國環磷醯胺(cyclophosphamide)市場的學名藥競爭,以及公司先前已溝通、正在進行的特定策略性產品退出所帶來的影響。本季結果主要來自我們美國業務的強勁表現,以及腹膜透析、急性腎臟治療與營養治療在全球的成長。
On the bottom line, adjusted earnings were $0.58 per diluted share. This reflects solid execution on the top line as well as the sustained momentum of our business transformation efforts.
在獲利方面,調整後每股稀釋盈餘為 0.58 美元。這反映我們在營收端的穩健執行,以及業務轉型工作所帶來的持續動能。
Now we'll walk you through performance by business, and I will be speaking to growth figures on an operational basis to provide a clearer understanding of underlying performance.
接下來我們將按事業別說明表現;為了更清楚呈現基本面表現,我將以營運基礎(operational basis)來談成長數據。
Global sales for Hospital Products were $1.6 billion, advancing 10% operationally. Breaking this out by business. Sales in Fluid Systems were $585 million, up 13% operationally. Performance was driven by IP Solutions' strength in the U.S., along with increased sales of IV Access sets, reflecting the ongoing pull-through from our growing SPECTRUM pump installed base.
醫院產品(Hospital Products)全球銷售額為 16 億美元,營運面成長 10%。按業務拆分如下。輸液系統(Fluid Systems)銷售額為 5.85 億美元,營運面成長 13%。表現主要由美國 IP Solutions 的強勁需求帶動,並且 IV Access 組件銷售增加,反映我們持續擴大的 SPECTRUM 幫浦裝機基礎所帶來的拉動效應(pull-through)。
Moving to Integrated Pharma Solutions, or IPS. Global sales were $552 million, increasing 4% operationally. Contributing to performance in the quarter was increased demand for the company's nutritional therapies globally and for premixed injectable drugs, enhanced drug reconstitution systems in the U.S.
接著談整合式製藥解決方案(Integrated Pharma Solutions,IPS)。全球銷售額為 5.52 億美元,營運面成長 4%。本季表現的貢獻因素包括:公司營養治療在全球需求增加,以及美國對預混注射劑藥品與強化型藥品復溶系統的需求提升。
We are continuing to bolster growth in the IPS business through both organic and inorganic opportunities particularly in the generic injectable pharmaceuticals. We remain on track to close our acquisition of Claris Injectables in the second half of 2017, which will greatly expand our marketed portfolio and pipeline.
我們持續透過有機與無機機會來強化 IPS 業務的成長,特別是在學名藥注射劑領域。我們仍按計畫於 2017 年下半年完成對 Claris Injectables 的收購,這將大幅擴充我們已上市產品組合與研發管線。
And in the first quarter, we announced a new strategic agreement with ScinoPharm, one of the world's leading API manufacturers to help develop, manufacture and commercialize 5 injectable drugs using a range of cancer treatments with an option to partner on an additional 15 molecules. In addition, we are preparing to launch 7 proprietary premixed injectable molecules in 2017 through our internal research and development pipeline. As we have stated previously, we tend to continue expanding our presence in the generic injectables space.
此外,在第一季我們宣布與 ScinoPharm 達成新的策略協議;ScinoPharm 是全球領先的原料藥(API)製造商之一,該協議將協助開發、製造並商業化 5 項注射劑藥品,涵蓋多種癌症治療,並可選擇就另外 15 個分子展開合作。另外,我們正準備在 2017 年透過內部研發管線推出 7 個專有的預混注射劑分子。如同我們先前所述,我們傾向持續擴大在學名藥注射劑領域的布局。
Moving to Surgical Care, which includes anesthesia and biosurgery. Total sales were $334 million, increasing 11% operationally. Performance in the quarter was fueled by strong U.S. growth for anesthesia and critical care products, driven primarily by increased demand for Transderm SCOP due to a temporary supply disruption in alternate product during the quarter. Increased sales of BREVIBLOC, a fast-acting IV beta-blocker, also contributed to the growth in the quarter.
接著談外科照護(Surgical Care),包含麻醉與生物外科(biosurgery)。總銷售額為 3.34 億美元,營運面成長 11%。本季表現受美國麻醉與重症照護產品的強勁成長帶動,主要因本季替代產品出現暫時性供應中斷,導致對 Transderm SCOP 的需求增加。BREVIBLOC(速效靜脈注射 β 阻斷劑)銷售增加,也對本季成長有所貢獻。
The BioSurgery business advanced mid-single digits on a global basis, driven by double-digit growth internationally of our core hemostats and sealants. As we have previously mentioned, we have increased our investments in this business. In an effort to turn around performance, we expect to begin recognizing the benefits of these actions towards the latter part of this year and beyond.
BioSurgery 業務在全球範圍內以中個位數成長,主要由我們核心止血劑與封合劑在國際市場的雙位數成長所帶動。如同先前提到的,我們已增加對此業務的投資。為了扭轉表現,我們預期將在今年稍晚以及之後開始認列這些行動所帶來的效益。
Some recent highlights include the acquisition of Wound Care Technologies, Incorporated, the manufacturer of the DermaClose Continuous Tissue Expander. DermaClose is a highly innovative device used to facilitate the suturing and the stapling of the skin around moderate to large wounds and represents our entry into a complementary product category.
近期亮點包括收購 Wound Care Technologies, Incorporated,該公司為 DermaClose 連續組織擴張器(Continuous Tissue Expander)的製造商。DermaClose 是一項高度創新的裝置,用於協助中度至大型傷口周圍皮膚的縫合與釘合,並代表我們進入一個互補的產品類別。
We also focused on enhancing growth organically. Earlier this month, we've unveiled costumer-centric enhancements to both our FLOSEAL and TISSEEL hemostatic agents that are designed to improve safety for patients and ease-of-use for clinicians.
我們也著重於以有機方式強化成長。本月稍早,我們公布了以客戶為中心的改良,針對 FLOSEAL 與 TISSEEL 兩款止血劑進行優化,旨在提升病患安全性並改善臨床人員的易用性。
And in March, we announced the publication of 2 compelling analyses in the Journal of Medical Economics supporting FLOSEAL as a cost-effective hemostat that may contribute to broader cost savings at hospitals as compared to other options.
此外,在 3 月,我們宣布《Journal of Medical Economics》刊登了兩項具說服力的分析,支持 FLOSEAL 作為具成本效益的止血劑;與其他選項相比,FLOSEAL 可能有助於醫院實現更廣泛的成本節省。
Finally, in the Hospital Products sales in our other category. We were $108 million, up 18%. Growth in the quarter benefited from continued demand for our contract manufacturing services, including our expertise in cytotoxic manufacturing in our Halle, Germany facility.
最後,在我們其他類別中的醫院產品(Hospital Products)銷售方面。我們為1.08億美元,成長18%。本季成長受惠於我們合約製造服務需求持續強勁,包括我們位於德國哈雷(Halle)廠在細胞毒性(cytotoxic)製造方面的專業能力。
During the first half of 2017, we expect higher growth for this business as we continue to anniversary the impact from one of our customers bringing manufacturing in-house.
在2017年上半年,隨著我們持續度過某位客戶將製造轉為內部生產所帶來影響的周年比較期,我們預期該業務將有更高的成長。
Turning to our Renal business. It's worth $896 million in the first quarter, up 2% operationally. Globally, peritoneal dialysis achieved mid-single-digit operational growth, reflecting an increase in patient base and ongoing market momentum of our new automated peritoneal dialysis or APD cyclers, AMIA in the U.S. and HOMECHOICE CLARIA for international markets. The success of AMIA and HOMECHOICE CLARIA APD is due in large part to our proprietary SHARESOURCE telemedicine technology, which recently surpassed 0.5 million patient treatments.
接著談我們的腎臟(Renal)業務。第一季規模為8.96億美元,按營運口徑成長2%。在全球範圍內,腹膜透析(peritoneal dialysis)達到中個位數的營運成長,反映病患基礎增加,以及我們新一代自動化腹膜透析(APD)循環機的市場動能持續,包括美國的AMIA與國際市場的HOMECHOICE CLARIA。AMIA與HOMECHOICE CLARIA APD的成功,很大一部分歸功於我們專有的SHARESOURCE遠距醫療技術,該技術近期已累計超過50萬次病患治療。
In a related development, Baxter also received the go for the order for a new Kaguya APD system in Japan, which we expect to launch later this year. Japan is a market in which we are looking to broaden our presence across the portfolio.
在相關進展方面,百特(Baxter)也已獲准在日本接單一套新的Kaguya APD系統,我們預期將於今年稍晚推出。日本是我們希望在整體產品組合中擴大布局的市場。
Renal growth in the quarter was impacted by a mid-single-digit decline in in-center hemodialysis globally. Positive performers -- performance, rather, in our U.S. in-center agency business was offset by lower sales internationally due to continued competitive pressures on dialyzers.
本季腎臟業務成長受到全球院內血液透析(in-center hemodialysis)中個位數下滑的影響。我們在美國院內機構(in-center agency)業務的良好表現,被國際市場因透析器(dialyzers)持續競爭壓力而導致的較低銷售所抵銷。
We continue to focus on enhancing the profitably of this business while also stabilizing the growth profile. The acute Renal business delivered solid mid-single-digit growth globally in the quarter. As we have previously mentioned, we believe the acute market holds substantial opportunity for us. And we are pleased to report that our next-generation leading-edge PrisMAX acute care technology now is being deployed for patients used in several European locations as part of the initial -- of an initial limited distribution. Clinician in-patient response today has been favorable, and we look forward to the full European commercial launch in 2018.
我們持續聚焦於提升該業務的獲利能力,同時也穩定其成長態勢。急性腎臟(acute Renal)業務本季在全球交出穩健的中個位數成長。如先前所提,我們相信急性市場對我們而言具有相當可觀的機會。我們也很高興報告,我們新一代、領先業界的PrisMAX急性照護技術,目前已在歐洲多個地點作為初期有限度配銷的一部分,開始部署供病患使用。目前臨床醫護人員與住院端的回饋良好,我們期待於2018年在歐洲全面商業上市。
In summary, our company-wide results for the quarter reflect our focus on disciplined executions of driving improved operational performance. Certainly, our business transformation efforts have been centered to margin expansion and we are by no means finished. We are pursuing several new fronts to accelerate these efforts, which we expect would generate incremental savings going forward, a portion of what -- which we tend to redeploy back into the businesses to drive innovation and growth.
總結而言,本季全公司層面的成果反映我們專注於以嚴謹的執行來推動營運表現改善。我們的業務轉型工作確實以擴大利潤率為核心,而我們絕非已完成。我們正從多個新面向加速推進這些工作,預期未來將帶來額外節省;其中一部分我們通常會再投入各項業務,以推動創新與成長。
The most important point to stress in closing is that we are on a continuing journey on our results this quarter, reinforce our confidence that we are on the right path to achieve our goal of sustained top quartile performance.
最後最重要的一點要強調的是:我們仍在持續前進的旅程中,而本季的成果進一步強化我們的信心,證明我們正走在正確道路上,以達成「長期維持同業前四分位」表現的目標。
With that, I will turn it over to Jay.
接下來我把時間交給Jay。
James K. Saccaro - CFO and Corporate VP
James K. Saccaro - CFO and Corporate VP
Thanks, Joe, and good morning, everyone. As Joe mentioned, we're pleased with our first quarter results, reflecting continued momentum towards delivering on our long-term financial goals.
謝謝你,Joe,各位早安。如Joe所提,我們對第一季的成果感到滿意,反映我們持續朝實現長期財務目標的方向累積動能。
Sales in the quarter increased 4% on a reported basis and 7% operationally, which was ahead of our expectations, driven by favorable performance in the Fluid Systems and Anesthesia businesses. Volume and mix were the primary drivers of growth in the quarter with price contributing approximately 1%.
本季銷售按報告口徑成長4%,按營運口徑成長7%,優於我們預期,主要由輸液系統(Fluid Systems)與麻醉(Anesthesia)業務的良好表現所帶動。本季成長的主要驅動因素為銷量與產品組合(mix),價格約貢獻1%。
Walking through the rest of the P&L. Adjusted gross margin of 44.3% represents an improvement of 200 basis points over the prior year, driven by improved pricing in select areas of the portfolio, favorable manufacturing performance and the benefit from our business transformation efforts aimed at simplifying the portfolio to drive efficiency and reduce costs.
接著說明損益表(P&L)的其餘項目。調整後毛利率為44.3%,較去年同期提升200個基點,主要受惠於產品組合中部分領域的定價改善、有利的製造表現,以及我們以簡化產品組合、提升效率並降低成本為目標的業務轉型措施所帶來的效益。
Adjusted SG&A totaled $560 million, decreasing 10% on a reported basis. The primary driver of the improvement was our ongoing focus on effectively managing our expense base to eliminate costs and reduce inefficiencies.
調整後銷售、一般及行政費用(SG&A)合計5.60億美元,按報告口徑下降10%。改善的主要驅動因素是我們持續專注於有效管理費用基礎,以消除成本並降低低效率。
Transition service agreement income totaled approximately $20 million in the quarter compared to approximately $28 million in the first quarter of 2016. TSA income from Shire will continue to decline as the need for these services ramps down, which is expected to be by mid-2017. For the year, we expect TSA income to decline by approximately $45 million versus 2016.
本季過渡服務協議(Transition Service Agreement, TSA)收入約2,000萬美元,去年2016年第一季約為2,800萬美元。來自Shire的TSA收入將隨著對這些服務的需求逐步降低而持續下滑,預期至2017年年中。就全年而言,我們預期TSA收入將較2016年減少約4,500萬美元。
Adjusted R&D spending in the quarter of $130 million decreased 4% versus the prior year. As Joe mentioned, we expect to continue to ramp up our investments in R&D to drive innovation and augment top line growth.
本季調整後研發(R&D)支出為1.30億美元,較去年同期下降4%。如Joe所提,我們預期將持續提高研發投資,以推動創新並增強營收成長。
Adjusted operating margin in the quarter was 16.4%, an improvement of 590 basis points versus the prior year. Operating margin compared favorably to our expectations, driven by improved gross margin and disciplined expense management.
本季調整後營業利益率為16.4%,較去年同期提升590個基點。營業利益率優於我們預期,主要由毛利率改善與嚴謹的費用管理所帶動。
Interest expense was $14 million in the first quarter. Adjusted other expense totaled $2 million in the quarter, reflecting a lower benefit from gains on balance sheet positions as compared to the prior year period. In addition, performance in the first quarter of 2016 benefited from dividend income from Baxalta and gains on the sale of select investments.
第一季利息費用為1,400萬美元。本季調整後其他費用合計200萬美元,反映相較去年同期,資產負債表部位的收益帶來的利益較少。此外,2016年第一季的表現受惠於來自Baxalta的股利收入,以及出售部分投資的收益。
The adjusted tax rate was 18.5% for the quarter, which reflects a benefit of $0.03 related to the adoption of new stock compensation guidance. And as previously mentioned, adjusted earnings of $0.58 per diluted share exceeded our guidance of $0.50 to $0.52 per share, driven principally by operational strength.
本季調整後有效稅率為18.5%,其中包含採用新的股份基礎薪酬指引所帶來的0.03美元利益。且如先前所提,調整後每股稀釋盈餘為0.58美元,高於我們每股0.50至0.52美元的指引,主要由營運強勁所驅動。
During the first quarter, we repurchased approximately $50 million or approximately 1 million shares. These targeted repurchases were more than offset by option-related dilution.
第一季期間,我們回購約5,000萬美元、約100萬股股份。這些針對性的回購,已被與選擇權相關的稀釋效應所抵銷。
Finally, before I turn to our updated outlook for 2017, I will provide some commentary regarding our cash flow performance in the quarter. During the first quarter, we generated free cash flow of $83 million, driven by strong operational performance, disciplined management of capital expenditures, which declined approximately $60 million to $123 million, along with continued focus on improving the company's working capital. This performance enhances our confidence that we are on track to achieve, if not exceed, our full year objective of approximately $1 billion of free cash flow.
最後,在我說明我們更新後的2017年展望之前,我先就本季現金流表現提供一些評論。第一季我們創造自由現金流8,300萬美元,主要由強勁的營運表現、資本支出(capital expenditures)的嚴謹管理所帶動(資本支出約減少6,000萬美元至1.23億美元),同時也持續聚焦改善公司的營運資金(working capital)。這項表現提升我們的信心,讓我們相信我們正按計畫達成、甚至可能超越全年約10億美元自由現金流的目標。
Let me conclude my comments by providing an update on our outlook for 2017. Starting with sales on a reported basis, including the impact of foreign exchange, we expect full year 2017 sales to increase between 1% to 2%; and on a constant currency basis, 2% to 3%. And after adjusting for the U.S. cyclophosphamide impact and select strategic product aggregates, we expect underlying operational growth of 4% to 5%.
我以更新我們對2017年的展望作為結語。先從按報告口徑的銷售(包含匯率影響)來看,我們預期2017年全年銷售將成長1%至2%;若以固定匯率(constant currency)計,成長2%至3%。此外,在調整美國環磷醯胺(cyclophosphamide)影響及部分策略性產品彙總項目後,我們預期基礎營運成長(underlying operational growth)為4%至5%。
All 3 of these sales ranges represent an increase from our prior guidance. This growth does not reflect any benefit from the proposed Claris acquisition, which, as Joe mentioned, we expect to close in the second half of 2017.
這三個銷售區間皆較我們先前的指引有所上調。此成長未反映擬議中的 Claris 收購案所帶來的任何效益;如 Joe 所提及,我們預期將於 2017 年下半年完成交割。
Following completion of the acquisition, we'll provide updated expectations. We now expect growth in the Hospital Products business of 2% to 3% on a constant currency and 4% to 5% on an operational basis.
收購完成後,我們將提供更新後的預期。我們目前預期醫院產品(Hospital Products)業務在固定匯率下成長 2% 至 3%,以營運基礎計算成長 4% 至 5%。
Within Hospital Products, we now expect Fluid Systems constant currency sales growth of 4% to 5% or 5% to 6% on an operational basis. For the Integrated Pharmacy Solutions business, we expect constant currency sales to decline low single digits.
在醫院產品之中,我們目前預期輸液系統(Fluid Systems)固定匯率銷售成長 4% 至 5%,或以營運基礎計算成長 5% 至 6%。至於整合藥局解決方案(Integrated Pharmacy Solutions, IPS)業務,我們預期固定匯率銷售將下滑低個位數。
We expect full year sales for cyclophosphamide to total $135 million as compared to our original guidance of $115 million. Our updated assumption is that additional competitors will enter during the third quarter of 2017.
我們預期環磷醯胺(cyclophosphamide)全年銷售額合計為 1.35 億美元,相較於我們原先指引的 1.15 億美元。我們更新後的假設為:將有更多競爭對手於 2017 年第三季進入市場。
On an operational basis, IPS sales are expected to increase approximately 4%. Within Surgical Care, we anticipate sales to grow approximately 3% constant currency or 3% to 4% operationally. And finally, for the Hospital Products business, we now expect EPS and other to increase high single digits. For the Renal business, we continue to expect full year constant currency sales to increase 3% to 4% or 4% to 5% operationally.
以營運基礎計算,IPS 銷售預期將增加約 4%。在外科照護(Surgical Care)方面,我們預期銷售在固定匯率下成長約 3%,或以營運基礎計算成長 3% 至 4%。最後,就醫院產品業務而言,我們目前預期 EPS 與其他項目將增加高個位數。至於腎臟(Renal)業務,我們仍預期全年固定匯率銷售成長 3% 至 4%,或以營運基礎計算成長 4% 至 5%。
Moving down the P&L, we now expect an operating margin of approximately 15.5% or approximately 200 basis points of improvement versus 2016, reflecting a strong first quarter performance and a lower impact from cyclophosphamide. As mentioned last quarter, we expect to provide updated long-term financial guidance on our second quarter earnings call.
往下看損益表(P&L),我們目前預期營業利益率約為 15.5%,較 2016 年改善約 200 個基點,反映第一季強勁表現以及環磷醯胺影響較低。如同上季所提及,我們預期將在第二季財報電話會議中提供更新後的長期財務指引。
We expect interest expense to total approximately $60 million and other income of approximately $15 million for 2017. For the year, we expect an average adjusted tax rate of approximately 21%. This is a slight increase in previous guidance, driven by the geographic mix of earnings.
我們預期 2017 年利息費用合計約 6,000 萬美元,其他收益約 1,500 萬美元。全年而言,我們預期平均調整後稅率約為 21%。這較先前指引略為上調,主要由獲利的地理分布所驅動。
For full year 2017, we anticipate an average share count of approximately $555 million. Based on these factors, we now expect 2017 adjusted earnings, excluding special items, of $2.20 to $2.28 per diluted share.
就 2017 全年而言,我們預期平均流通股數約為 5.55 億股。基於上述因素,我們目前預期 2017 年調整後盈餘(不含特殊項目)為每股稀釋後 2.20 至 2.28 美元。
And finally, for the year, we continue to expect to generate operating cash flow of approximately $1.75 billion, and as I mentioned earlier in my prepared remarks, free cash flow of approximately $1 billion.
最後,全年我們仍預期可產生約 17.5 億美元的營運現金流;且如我先前在準備稿中提到,自由現金流約為 10 億美元。
Specific to the second quarter of 2017, we expect sales to increase approximately 2% on a constant currency basis and to be comparable to the prior year on a reported basis. Operationally, sales in the second quarter are expected to increase approximately 3%. And we expect adjusted earnings, excluding special items, of $0.55 to $0.57 per diluted share.
針對 2017 年第二季,我們預期銷售在固定匯率基礎下成長約 2%,以報告基礎(reported basis)計算則與去年同期大致相當。以營運基礎計算,第二季銷售預期將增加約 3%。我們並預期調整後盈餘(不含特殊項目)為每股稀釋後 0.55 至 0.57 美元。
With that, we can now open the call up for Q&A.
接下來,我們可以開放進入問答環節。
Operator
Operator
(Operator Instructions) And our first question comes from Matt Taylor of Barclays.
(接線員指示)我們的第一個問題來自 Barclays 的 Matt Taylor。
Matthew Charles Taylor - Director
Matthew Charles Taylor - Director
I guess, the first question I had, I wanted to understand in your guidance what you're assuming for some of the new things like Claris, the ScinoPharm partnership and the contribution from the molecules that you talked about launching as you sold that injectable stuff.
我想,我的第一個問題是,我想了解在你們的指引中,對一些新事項的假設是什麼,例如 Claris、與 ScinoPharm 的合作夥伴關係,以及你們談到在出售那項注射劑業務時所提及、將要推出的那些分子所帶來的貢獻。
James K. Saccaro - CFO and Corporate VP
James K. Saccaro - CFO and Corporate VP
Sure. Good morning, Matt. Thanks for the question. With respect to Claris, we've included no impact from that transaction. We expect that the transaction will close in the second half. Upon closing the transaction, we will provide updated guidance, both from sales and an EPS standpoint. As it relates to ScinoPharm, there is really no material impact in 2017. The large majority of those molecules will launch in 2020. So we have a few years before we start to experience the benefits from that important partnership. And then finally from the other injectable products, we haven't broken out the specific sales related to the [Carrera] molecules. What we have said is we expect the original set of molecules to generate approximately a little north of $200 million in annual sales, but that ramps up over a number of years. In 2017, the impact is still modest. So what I would say overall is we're very excited about the generic injectable space. It's an area where we believe Baxter can win and do very well. But we're really setting the stage for that success in the first half and second half of 2017.
當然。早安,Matt。謝謝你的提問。關於 Claris,我們未將該交易的任何影響納入。我們預期該交易將於下半年完成交割。交易完成後,我們將從銷售與 EPS 兩個面向提供更新後的指引。至於 ScinoPharm,2017 年實際上不會有任何重大影響。其中絕大多數分子將於 2020 年推出。因此,在我們開始體驗這項重要合作帶來的效益之前,還有幾年的時間。最後,關於其他注射劑產品,我們尚未將與 [Carrera] 分子相關的特定銷售額單獨揭露。我們所說的是,我們預期最初那一組分子每年可帶來略高於 2 億美元的銷售額,但會在數年內逐步爬升。在 2017 年,其影響仍屬有限。因此,我想整體而言,我們對學名注射劑領域感到非常振奮。這是我們相信 Baxter 能夠勝出並且表現非常出色的領域。但我們確實是在 2017 年上半年與下半年為那項成功奠定基礎。
Matthew Charles Taylor - Director
Matthew Charles Taylor - Director
Okay, Jay. And then I just wanted to see if you could give us a little bit more color about what's going on in the Renal business. That's an area where we'd expect that you might do a little bit better this quarter with the launch of AMIA and you continue to see a little bit below market growth there. So what can get that to pick up? And I guess what's causing kind of the lower-than-average growth in that segment now?
好的,Jay。接著我想看看你是否能再多提供一些關於腎臟業務現況的細節。這是我們原本預期你們在本季可能會因 AMIA 上市而表現更好一些的領域,但你們仍持續呈現略低於市場的成長。那麼,什麼因素能讓它加速回升?以及我想,現在該部門成長低於平均的原因是什麼?
José E. Almeida - Chairman, CEO and President
José E. Almeida - Chairman, CEO and President
Matt, the performance of our Renal business in the PD, peritoneal dialysis, and acute Renal care, is doing very well. And because we are market leaders in both of them, our growth for the vast majority dictates the growth to the market. We have added a good number of patients for the PD business, and AMIA has been a tremendous success in the U.S. As a matter of fact, the growth is at or above what we have said before in terms of market. The issue that we have is simply in-center HD and is focused in Europe for the vast majority. We have had -- we spent amount of competition, a price competition actually in Europe on the dialyzer, and we have plans to come back at that with growth opportunities in Asia to offset that. And now our issue in Renal is primarily Europe in-center HD, and we are attentively looking at that. Just a note on the general business of Baxter for Europe, we have made significant change in management and as well as country management. We had really vamped in that organization and looking forward to the new folks to make an impact. So that's the area of focus that we have right now. But in terms of the Renal business, not only we are very happy with the PD business and acute Renal care. As a matter of fact, acute Renal care, we are taking market share in the U.S. as we speak. We continue to convert a large rate -- in large rate hospitals in the U.S. And the profitability most importantly has increased significantly in the Renal business. So we're quite happy with that. So the focus, as I said, is fixed in Europe in-center HD.
Matt,我們腎臟業務在 PD(腹膜透析)以及急性腎臟照護(acute Renal care)方面的表現非常好。而且因為我們在這兩個領域都是市場領導者,我們在絕大多數情況下的成長基本上也決定了市場的成長。我們在 PD 業務新增了相當多的病患,而 AMIA 在美國也非常成功。事實上,就市場成長而言,其成長率達到或高於我們先前所說的水準。我們面臨的問題其實僅在院內血液透析(in-center HD),而且主要集中在歐洲。我們在歐洲的透析器(dialyzer)遭遇了競爭——實際上是價格競爭;我們也規劃透過亞洲的成長機會來抵銷其影響。因此,目前我們腎臟業務的問題主要在歐洲的院內血液透析,我們正密切關注。另外補充一下,針對 Baxter 在歐洲的整體業務,我們已在管理層以及各國管理團隊做出重大調整。我們確實已大幅強化該組織,也期待新團隊能帶來影響。所以這就是我們目前的重點聚焦領域。但就腎臟業務而言,我們不僅對 PD 業務與急性腎臟照護非常滿意。事實上,就在此刻,我們在美國的急性腎臟照護正在取得市占率。我們持續在美國的大型醫院以很高的速度推動轉換。而最重要的是,腎臟業務的獲利能力已顯著提升。因此我們對此相當滿意。正如我所說,我們的焦點鎖定在歐洲的院內血液透析。
Operator
Operator
And our next question comes from Vijay Kumar of Evercore ISI.
我們的下一個問題來自 Evercore ISI 的 Vijay Kumar。
Vijay Muniyappa Kumar - MD and Fundamental Research Analyst
Vijay Muniyappa Kumar - MD and Fundamental Research Analyst
Maybe the first one, a big picture question for Joe. We've had a number of deals hit the pay up recently. A lot of consolidation. Just given your thoughts on portfolio optimization rate, some of the valuations seem here pretty healthy. I'm just curious how you're thinking of acquisitions tuck-ins versus even possibly divestitures.
也許第一個問題,給 Joe 一個宏觀層面的問題。最近我們看到不少交易需要提高出價(pay up)。也有很多整併。就您對投資組合優化節奏的看法而言,目前一些估值看起來相當不錯。我想請教您如何看待併購中的補強型收購(tuck-ins)相較於甚至可能的資產剝離(divestitures)。
José E. Almeida - Chairman, CEO and President
José E. Almeida - Chairman, CEO and President
Vijay, good morning. My perspective has not changed about where Baxter stands. We're open to the tuck-ins, and we're doing them. And we're working very hard to get even more opportunities. We have a good pipeline in our pharmaceutical business between partnership and some tuck-ins and even in our advanced surgery Baxter business. With the performance of the company and the work that Jay and Cathy Skala have done in our business transformation process and how quick we're integrating and simplifying our back office, I feel more confident that Baxter could do a 20%, 25% of our market cap deal without a problem, okay? Doesn't mean that we're going to do it, but my confidence has increased in the management of the company in really pulling off something that would be a good deal for our shareholders in terms of bringing synergies to the bottom line and a good accretion for the top line.
Vijay,早安。我對 Baxter 所處位置的看法沒有改變。我們對補強型收購持開放態度,而且我們也正在做。我們也非常努力在爭取更多機會。在我們的製藥業務方面,無論是合作夥伴關係或一些補強型收購,甚至在我們的先進外科 Baxter 業務上,我們都有不錯的案源管線。隨著公司表現,以及 Jay 和 Cathy Skala 在業務轉型流程中所做的工作,還有我們整合與簡化後勤(back office)的速度,我更有信心 Baxter 可以在沒有問題的情況下做一筆相當於我們市值 20%、25% 的交易,好嗎?這不代表我們一定會做,但我對公司管理團隊的信心提高了,能真正完成一筆對股東有利的交易——在損益表底線帶來綜效,並在營收端帶來良好的增益(accretion)。
Vijay Muniyappa Kumar - MD and Fundamental Research Analyst
Vijay Muniyappa Kumar - MD and Fundamental Research Analyst
That's helpful. And then maybe one follow-up for Jay. Jay, I mean, operating margins was impressive, right. It really was. But when you look at the guidance of 15.5% versus what you did in the quarter, right, it sort of implies maybe 15-ish in the back half. Maybe the delta, it sounds this is TSA maybe cyclo. I'm just curious is there anything else going on the operating margin line?
這很有幫助。接著也許給 Jay 一個追問。Jay,我是說,營業利益率很亮眼,對吧。確實如此。但當你看 15.5% 的指引相較於你們本季的表現,對吧,這似乎暗示下半年可能在 15% 左右。這個差異聽起來可能是 TSA 以及 cyclo(環磷醯胺)。我想請教,營業利益率這一行還有其他因素在發生嗎?
James K. Saccaro - CFO and Corporate VP
James K. Saccaro - CFO and Corporate VP
Great. Yes, from the first half to the second half, there are a couple of drivers that impact the operating margin and EPS. Just to run through those, one is cyclophosphamide. From first half to second half, we expect $40 million run rate decline. And so that's about $0.06 of impact. We also expect a ramp down in TSAs of approximately $30 million. So that's roughly $0.04 of impact. And then the other important thing that we're doing in the second half of the year is we're accelerating some investments in R&D. It's important for us to really set the stage for accelerating growth in the future. It has been a core area of focus for us over the last 8 quarters. And so for us, we are ramping up some spending about $40 million or roughly $0.07 of impacts related to first half to second half increases in R&D spending. The final point I would make with respect to second half EPS nonoperating margin is the tax rate. Because the primary source of benefit related to the new stock option exercise and stock issuance guideline is a first quarter impact, the tax rate picks up in the second half of the year, roughly $0.03. So interestingly, if you total all of these, we're talking about $0.20 of impact in the second half of the year or roughly $100 million, $110 million, $120 million worth of pretax impact in the second half. So that's really the drivers as to why we're not seeing the standard rates of growth that we've seen previously in the second half of this year.
好的。是的,從上半年到下半年,有幾個驅動因素會影響營業利益率與 EPS。我快速說明一下,其中之一是 cyclophosphamide(環磷醯胺)。我們預期從上半年到下半年,其 run rate 會下降 4,000 萬美元。因此大約影響 $0.06。我們也預期 TSA 會下滑約 3,000 萬美元。因此大約影響 $0.04。另外一個我們在下半年要做的重要事情,是加速一些研發(R&D)投資。這對我們而言很重要,能為未來加速成長奠定基礎。這一直是我們過去 8 個季度的核心重點領域。因此,我們會把支出提高約 4,000 萬美元,或約 $0.07 的影響,這與從上半年到下半年研發支出增加有關。最後一點,關於下半年 EPS 的非營業項目(nonoperating)/稅後利潤率,我要提的是稅率。由於與新的股票選擇權行使及股票發行指引相關的主要利益來源是在第一季反映,因此稅率在下半年會回升,約影響 $0.03。有趣的是,如果把這些全部加總,我們談的是下半年約 $0.20 的影響,或約 1 億到 1.1 億、1.2 億美元的稅前影響。所以,這些就是為什麼我們在今年下半年看不到先前那種標準成長率的主要驅動因素。
Operator
Operator
And our next question comes from Mike Weinstein with JPMorgan.
我們的下一個問題來自 JPMorgan 的 Mike Weinstein。
Michael N. Weinstein - Senior Medical Technology Analyst and Head of Healthcare Group within Equity Research
Michael N. Weinstein - Senior Medical Technology Analyst and Head of Healthcare Group within Equity Research
Joe, you keep raising that percentage. Today you said 20% to 25% of market cap for the upside of the size on M&A versus 15% to 20% prior. Is that where you're headed now that bigger deals were making more sense than maybe 12 months ago?
Joe,你一直在提高那個百分比。今天你說,併購(M&A)在規模上上行空間可達市值的 20% 到 25%,而之前是 15% 到 20%。這是否代表你現在的方向是:相較於 12 個月前,更大的交易開始變得更有意義?
José E. Almeida - Chairman, CEO and President
José E. Almeida - Chairman, CEO and President
Mike, you have good memory. And I'm happy that you listen to what I say. We do have more confidence in Baxter. First of all, as a new CEO of last year, you're just getting to know the company. You're getting to know the management and its capabilities. Now we have a solid team, very, very good team. And the execution has been great. So that gives me confidence that we can do something bigger if the opportunity arises and things are in the right place and there's value for our shareholders, never compromising what we think is our primary reason in doing deals, which is the deliver more value to our shareholders. So basically, our confidence goes up, the percentage goes up. And I think it's really reasonable to assume there's an opportunity. Baxter has the balance sheet, has the borrowing capability, and we feel comfortable with that.
Mike,你記性很好。而且我很高興你有在聽我說的話。我們對 Baxter 的信心確實更高了。首先,作為去年新上任的 CEO,你只是剛開始了解公司。你也在了解管理團隊及其能力。現在我們有一個穩健的團隊,非常、非常好的團隊。而且執行表現很出色。因此,如果機會出現、條件到位,且能為股東創造價值,這讓我有信心我們可以做更大的事情;同時我們絕不會犧牲我們認為做交易的首要原因,也就是為股東交付更多價值。所以基本上,我們的信心上升,百分比就上升。我認為合理地假設存在這樣的機會。Baxter 有資產負債表實力,也有舉債能力,我們對此感到安心。
Michael N. Weinstein - Senior Medical Technology Analyst and Head of Healthcare Group within Equity Research
Michael N. Weinstein - Senior Medical Technology Analyst and Head of Healthcare Group within Equity Research
Okay, there's a couple quick financial follow-ups if you don't mind. So one, you didn't raise your operating cash flow guidance. And I know you raised your -- effectively your net income guidance by $50 million, and you had a very strong cash flow quarter, so maybe, if you could shed some light on that. And then second, can you just give us more on what's going on in the SG&A line and then what we have so far? And maybe give us a sense of headcount changes or anything else you can share. Your underlying SG&A expense was down 10.5% this quarter. But obviously pretty dramatic and it's hard for us outside the company to see some of those changes that are going on.
好的,如果你不介意,我有幾個很快的財務追問。第一,你沒有上調營運現金流指引。我知道你把——實質上把淨利指引上調了 5,000 萬美元,而且本季現金流非常強勁,所以也許你可以說明一下原因。第二,你能否多談一些 SG&A 這一行目前發生了什麼,以及到目前為止我們看到的情況?也許可以讓我們了解一下人力編制(headcount)的變化或任何你能分享的其他資訊。你們本季的基礎 SG&A 費用年減 10.5%。但顯然幅度相當大,對我們這些公司外部的人來說,很難看清楚其中正在發生的變化。
James K. Saccaro - CFO and Corporate VP
James K. Saccaro - CFO and Corporate VP
Sure. First, as it relates to cash flow. Great performance in the quarter and it was definitely a little bit ahead of our expectations. It was certainly ahead of last year. But as you will remember, Mike, we did have a tax payment last year that distorted the Q1 results. But importantly, the pieces that I think we are pleased with, days payable we held flat, but days inventory on hand we improved 16 days roughly year-over-year. DSO was down 9 days year-over-year. So this relentless focus on working capital balances is paying dividends and the teams are hard at work driving the results in this regard. The other piece of this relates to CapEx, where we continue to focus on driving savings where possible, taking a zero-based approach to CapEx and capital spending. The reason we haven't raised guidance, I said -- in my prepared remarks I said, our confidence in our ability to beat or exceed guidance has increased. So much of our free cash flow is concentrated in the fourth quarter of the year that it's very difficult to have a line of sight at exactly how payables and receivables will land at year-end. And given the back-end load of cash flow, it's a very volatile number. So I think for us, we have an improved line of sight, increasing level of confidence. We'll watch this throughout the year and perhaps on the -- if things continue along the current trend, in Q2 or Q3, we'll be able to update guidance and provide some updated numbers in that regard. As it relates to the SG&A initiatives, yes, I will tell you, we, as a team, are very proud of the progress that we've made in the transformation of Baxter. We started this in the second half of 2015. You will recall, really accelerated the efforts in earnest in 2016. And our business transformation office led by Cathy Skala it is focused on a number of important initiatives. One of them relates to zero-based budget. And I will say that in 2017, in the first quarter, we benefited from a lot of the zero-based efforts that we put in place last year related to organization efficiencies, related to spending initiatives. So really, the primary driver of the benefit in the first quarter was driven by many of these savings initiatives that we initiated last year. And then the other thing that we've done is for the back office functions, principally finance, IT, HR, we started an initiative to drive and improve the efficiency of those functions. The most notable area to-date, the most achievement in this area has been led by our IT team. So Paul Martin, our CIO, and his entire organization have been incredibly focused on creatively driving down the cost of the IT infrastructure. And so that was one element of driving improvement in the first quarter. So those are a few of the highlights, I would say. We'll stop short of getting into specific headcount. We have delineated this program in detail in our 10-K where we talk about the spending requirements to the program but also the overall savings programs. And I would say that this is very much tracking in-line or ahead of expectations at this point.
當然。首先,就現金流而言。本季表現非常出色,確實略優於我們的預期。也確實優於去年。但如你所記得的,Mike,我們去年確實有一筆稅款支付,扭曲了第一季的結果。但重要的是,我認為我們感到滿意的幾個部分:應付帳款週轉天數我們維持持平,但存貨在手天數(DIO)年對年約改善了16天。應收帳款週轉天數(DSO)年對年下降了9天。因此,對營運資金各項餘額的持續專注正在帶來成效,團隊也正全力以赴推動這方面的成果。另一部分與資本支出(CapEx)相關,我們持續聚焦在可行之處推動節省,並以零基礎的方式看待CapEx與資本支出。至於我們為何尚未上調指引,我說過——在我事先準備的談話中我提到,我們對於超越或達成指引的信心已提高。由於我們的自由現金流很大一部分集中在第四季,因此很難精準掌握年底時應付與應收將落在什麼水準。而且在現金流後段集中之下,這個數字波動性很大。所以對我們而言,我們的能見度有所改善,信心程度也在提升。我們會在全年持續觀察;若情況延續目前趨勢,可能在第二季或第三季,我們將能更新指引並提供一些更新的數字。至於SG&A(銷售、一般及行政費用)相關的倡議,是的,我可以告訴你,我們作為一個團隊,對於在Baxter轉型上取得的進展感到非常自豪。我們在2015年下半年開始推動。你會記得,我們在2016年確實大幅加速、認真投入這些工作。而由Cathy Skala領導的業務轉型辦公室,正聚焦於多項重要倡議。其中之一與零基礎預算(zero-based budget)相關。我也要說,在2017年第一季,我們受益於去年建立的許多零基礎措施,包括組織效率提升、以及支出相關的倡議。因此,第一季效益的主要驅動因素,來自我們去年啟動的多項節省計畫。另外,我們針對後勤(back office)職能——主要是財務、IT、人資——啟動了一項提升這些職能效率的計畫。截至目前最顯著的領域、在這方面最大的成果,是由我們的IT團隊所帶動。因此,我們的CIO Paul Martin及其整個組織,一直非常專注於以創新方式降低IT基礎設施成本。而這也是推動第一季改善的其中一個要素。以上是我認為的一些重點。我們先不深入到具體的人力編制數字。我們已在10-K中詳細說明此計畫,包含計畫所需的支出需求,以及整體的節省方案。我會說,截至目前這項計畫的進度非常符合、甚至優於預期。
Operator
Operator
And our next question comes from David Lewis of Morgan Stanley.
下一個問題來自Morgan Stanley的David Lewis。
David Ryan Lewis - MD
David Ryan Lewis - MD
Maybe a quick one on long-term guidance for Joe or Jay. So as it relates to long-term guidance next quarter, you've been pretty transparent about that. I think investors are very focused on margins, Joe. And I think given your comments on your comfort in transformation, it sounds like we've got a material update as it relates to margins. But I wonder if you could talk about organic growth transformation for a second. Have you seen enough from some of the pipeline developments in biosurgery and the continued traction in Renal and Fluid Systems to kind of have a fundamentally different view for how this business can grow in the future from an organic perspective?
也許針對Joe或Jay問一個關於下季長期指引的簡短問題。就下季的長期指引而言,你們一直相當透明。我認為投資人非常關注利潤率,Joe。而且根據你對轉型進展的信心評論,聽起來我們會在利潤率方面看到一個重大的更新。但我想請你談談有機成長的轉型。你是否已從生物外科(biosurgery)的一些產品管線進展,以及腎臟與輸液系統(Renal and Fluid Systems)持續的動能中,看到足夠的跡象,使你對於這項業務未來以有機方式成長的能力,有一個根本不同的看法?
José E. Almeida - Chairman, CEO and President
José E. Almeida - Chairman, CEO and President
David, I would say that all the efforts that we're putting into innovation and the better deployment of R&D dollars and portfolio management are all starting to give us more comfort that our top line growth can be augmented organically towards the end of '17 into '18. Those are not overnight programs. Those are programs that take a significant amount of time if you know our products. Even our hemostats, those are long-term studies that need to be done. But as what I've seen so far, coming out our R&D reviews and portfolio business reviews, that we're going to start getting momentum towards the end of this year, beginning next year were the things that we started since we started as CEO. I would say that there is some very notable upticks in areas like PD, with AMIA and HOMECHOICE CLARIA. We are seeing the launch of some technologies across the board that were not before emphasized by the company such as our extracorporeal technologies as well as our acute Renal care new technology, PrisMAX. So I tell our investors that there's a significant focus in innovation, but innovation is the part that takes a little longer. And we'll see that hitting mostly in '18. Our story is one of providing value to the shareholder. We went very hard at our cost structure as well as our efficiencies, selling products in the market, you can see that. The Claris acquisition will bring some really good molecules between 150 to 175. I gave the team, led by Robert Felicelli, a specific goal that by 2021, we need to have more than 300 molecules in the marketplace as well as understanding any potential pipeline of biosimilars. So we are just in the beginning of our journey to develop a really strong top line organic growth company. And in the meantime, to deliver value to our shareholders, we are hitting everything that we can in terms of making this company the most efficient and effective in everything we do.
David,我會說,我們在創新、以及更有效部署研發(R&D)資金與產品組合管理上所投入的所有努力,都開始讓我們更有信心:我們的營收成長在2017年末到2018年期間,可以透過有機方式得到提升。這些不是一夕之間就能完成的計畫。如果你了解我們的產品,你就知道這些計畫需要相當長的時間。即便是我們的止血產品(hemostats),也需要進行長期研究。但就我目前所看到的,從我們的研發檢視與產品組合業務檢視來看,我們自從我擔任CEO以來所啟動的事項,將在今年底、明年初開始帶來動能。我會說,在PD(腹膜透析)等領域出現了一些非常明顯的上升趨勢,包含AMIA與HOMECHOICE CLARIA。我們也看到一些技術在各領域陸續推出,這些過去並未被公司特別強調,例如我們的體外循環(extracorporeal)技術,以及我們急性腎臟照護的新技術PrisMAX。因此我告訴投資人,我們在創新上投入了大量焦點,但創新這一塊需要更長的時間才能顯現。而我們將主要在2018年看到其成果落地。我們的故事核心是為股東創造價值。我們在成本結構與效率提升上非常積極,同時也在市場上銷售產品,你們可以看到這一點。Claris的收購將帶來一些非常好的分子(molecules),數量約在150到175之間。我也給了由Robert Felicelli領導的團隊一個明確目標:到2021年,我們需要在市場上擁有超過300個分子,同時也要了解任何潛在的生物相似藥(biosimilars)產品管線。因此,我們才剛開始打造一家具備強勁營收端有機成長能力的公司之旅。同時,為了向股東交付價值,我們會在各方面全力以赴,讓公司在我們所做的一切上都成為最有效率、最有效能的企業。
David Ryan Lewis - MD
David Ryan Lewis - MD
Okay, Joe. Very, very clear. Let me just -- a quick couple of follow-ups for Jay. Jay, just second quarter numbers seem a little conservative to some modest comp adjusted deceleration. It is your toughest comp of the year. But the question is just is there anything momentum perspective in your mind that really changes into the second quarter? Or is that just the comp? And then Fluid Systems really significant upside relative to our number. Can you just give us a snapshot of what's happening with momentum right now between pumps, disposable pull-through and price?
好的,Joe。非常、非常清楚。我再——針對Jay快速追問兩點。Jay,第二季的數字看起來相對保守,似乎在經過適度的可比調整後出現一些放緩。那確實是你們全年最艱難的可比基期。但問題是,從動能角度來看,你是否認為第二季真的有任何改變?還是那只是可比基期的因素?另外,輸液系統(Fluid Systems)的表現相對於我們的預估有非常顯著的上行。你能否簡要說明一下目前動能的狀況——在幫浦、耗材帶動(disposable pull-through)以及價格之間,各自發生了什麼?
James K. Saccaro - CFO and Corporate VP
James K. Saccaro - CFO and Corporate VP
Sure. First, as it relates to Q2, to your point, David, it is the most difficult comp of the year. Q2 last year, we had 12% growth in the U.S., so really strong performance. And we had a very strong pump placement quarter, along with strong sales in our Surgical Care area. So from a comp standpoint, it's a challenging one. I would say there's 2 other factors in play that are factors that are well understood from our perspective. First is Fluid Systems in the U.S., 20% growth, we do expect that to come down over time as we anniversary certain agreements and as we start to get to a more steady-state approach from a pump placement and sets growth standpoint. So that 20% growth is not a number that we expect to see for the continued future. That will moderate down. And then the other factor is, as Joe referenced in his comments regarding sales, we did have a bolus of sales related to a product called Transderm SCOP about $20 million or so of sales in the first quarter. We expect the alternate supplier to be back on the market. In fact, they are on the market. So now those sales will moderate down. That benefit will be more muted as we look to the second quarter. So what I will tell you is it is, however, consistent with our original expectations from a sales growth standpoint. As it relates to the Fluid Systems business, 20% growth in the U.S., 0% international. If we're to exclude strategic exits, we would see 3% international growth, 12% growth overall or 13% on an operational basis, excluding the strategic exit. Really the way to think about that, our infusion systems was high single digit growth and really with the pumps -- it wasn't really a pump story. It was more about the sets associated with the pumps because we had good pump placements in Q1 of last year. And so we saw double-digit near-teens growth from a sets standpoint. Our whole theory in terms of our pumps business is as we grow the installed base, it sets right along at a higher margin and it helps transform the margin profile of the company. That clearly played out with the Q1 result with the double-digit growth in sets. And then the IDE business in the first quarter in the U.S., we saw a very significant growth, north of 20%. And that was very much a mix of volume along with some pricing. So again, it was ahead of our expectations overall. We're pleased with the progress there and continue to focus on driving sales of the SPECTRUM pump because that's such an important aspect of our overall business.
當然。首先,就第二季而言,如你所說,David,這是全年最難比較的基期。去年第二季,我們在美國有12%的成長,表現非常強勁。而且我們在幫浦投放(pump placement)方面有非常強的一季,同時我們外科照護(Surgical Care)領域的銷售也很強。所以從比較基期的角度來看,這是一個具挑戰性的季度。我會說另外還有兩個因素在發揮作用,從我們的角度來看,這些因素是大家都很清楚的。第一個是美國的流體系統(Fluid Systems),成長20%;我們確實預期這個數字會隨時間下降,因為我們會進入某些協議的周年期,並且在幫浦投放與耗材組(sets)成長方面開始回到較穩態的做法。因此,20%的成長不是我們預期未來會持續看到的數字。它會趨於溫和下滑。另一個因素是,如Joe在談到銷售時所提到的,我們第一季確實有一筆與名為Transderm SCOP的產品相關的銷售挹注,大約2,000萬美元左右。我們預期替代供應商會回到市場。事實上,他們已經回到市場了。因此現在這些銷售將會回落。當我們看第二季時,這項利多會更為淡化。不過我要說的是,從銷售成長的角度來看,這仍與我們原先的預期一致。就流體系統業務而言,美國成長20%,國際為0%。如果排除策略性退出(strategic exits),我們會看到國際成長3%,整體成長12%,或以營運基礎(operational basis)計算、排除策略性退出後為13%。真正的理解方式是:我們的輸注系統(infusion systems)是高個位數成長,而就幫浦而言——其實不太是幫浦本身的故事。更多是與幫浦相關的耗材組(sets),因為我們在去年第一季有不錯的幫浦投放。因此從耗材組的角度,我們看到雙位數、接近十幾%的成長。我們對幫浦業務的整體理論是:隨著我們擴大裝機基礎(installed base),耗材組會以更高毛利同步成長,並有助於改善公司的毛利結構。這在第一季的結果中很明顯地展現出來,耗材組出現雙位數成長。另外,第一季在美國的IDE業務,我們看到非常顯著的成長,超過20%。這很大程度是量的組合,再加上一些價格因素。所以整體而言,它再次超出我們的預期。我們對那裡的進展感到滿意,並將持續專注於推動SPECTRUM幫浦的銷售,因為那是我們整體業務非常重要的一環。
Operator
Operator
And our next question comes from Larry Biegelsen of Wells Fargo.
下一個問題來自富國銀行(Wells Fargo)的Larry Biegelsen。
Lawrence H. Biegelsen - Senior Analyst
Lawrence H. Biegelsen - Senior Analyst
Yes, I wanted to ask about the Renal pipeline and then one on M&A. So Joe, you've talked about being excited about the acute Renal pipeline in new areas. But I don't think you've given us much color on that. And also can you talk about the point of care PD regulatory pathway? How close are you to getting FDA sign-off on that trial? And then I just have one follow-up.
是的,我想問一下腎臟(Renal)產品線的研發管線,然後再問一個關於併購(M&A)的问题。Joe,你談到你對急性腎臟(acute Renal)在新領域的研發管線感到很興奮。但我覺得你們沒有提供太多細節。另外,你能談談即時照護(point of care)PD的法規路徑嗎?你們距離取得FDA對該試驗的核准(sign-off)有多近?然後我還有一個追問。
José E. Almeida - Chairman, CEO and President
José E. Almeida - Chairman, CEO and President
Hi, Larry. The Renal pipeline is one of the richest that we have right now. And we reorganized our company that would squarely, under the general managers and presidents of the businesses, the research and development management. So that is -- with people there we bought -- that we brought from other companies to Baxter. It has enhanced significantly our ability to not only develop, put products in the market, but also accelerated clinical studies that we're doing. So give an example, we're very excited about THERANOVA. We're going to be investing in the next few years $25 million in clinical data because we are convinced and have sufficient data in hand right now that proves this product is superior to any dialyzer in the market today. When it comes to acute Renal care, we have great products for sepsis treatment. We're going to continue to double [diagnosis] places like Japan and bring back technology on a global basis. And then let me talk about the point of care. A lot has been said by a bunch of different people about point of care and our PD and all the stuff. And Baxter is the -- probably the only company that has the capability to vertically integrate all these technologies. And to that end, we'll be putting our first patient on point-of-care treatment at the towards the end of 2018. So we have a very strong belief and our best way is now determined that we can do that. So that is a great achievement the chronic Renal team that has put that together. So as I say to the folks at Baxter in our goal, go compete for the dollars, go show the best ROIC and Renal has done a great job so far. I hope the other divisions will follow through and go fight for that dollar that we have available for product development and clinicals.
嗨,Larry。腎臟研發管線是我們目前最豐富的之一。我們也重新組織了公司,將研發管理明確地納入各事業的總經理與總裁的管理之下。因此——加上我們從其他公司延攬到Baxter的人才——這大幅提升了我們不僅能開發並將產品推向市場的能力,也加速了我們正在進行的臨床研究。舉例來說,我們對THERANOVA非常興奮。未來幾年我們將投資2,500萬美元在臨床數據上,因為我們深信且目前手上已有足夠數據證明,這個產品優於目前市場上的任何透析器(dialyzer)。在急性腎臟照護方面,我們有很好的敗血症(sepsis)治療產品。我們將持續加倍投入[診斷]在像日本這樣的地點,並把技術以全球方式帶回來。接著讓我談談即時照護(point of care)。很多不同的人談了很多關於即時照護、我們的PD以及各種事情。而Baxter大概是唯一一家有能力把這些技術做垂直整合的公司。為此,我們將在2018年底左右讓第一位病人接受即時照護治療。因此我們非常有信心,而且我們現在已經確定這是我們能做到的最佳方式。這是慢性腎臟(chronic Renal)團隊促成的一項重大成就。所以我對Baxter的同仁說,在我們的目標之下:去競爭資金、去展現最佳的投資資本報酬率(ROIC),而腎臟事業到目前為止做得非常好。我希望其他事業部也能跟進,去爭取我們可用於產品開發與臨床研究的那筆資金。
Lawrence H. Biegelsen - Senior Analyst
Lawrence H. Biegelsen - Senior Analyst
Joe, that's really helpful. Just one clarification on that and one follow-up. The first patient on point of care by the end of 2018, is that the first patient in your clinical trial? Or is that when you're basically saying when you can launch?
Joe,這非常有幫助。我想就此做一個澄清,然後再追問一個問題。你說在2018年底前讓第一位病人進入即時照護(point of care),那是指你們臨床試驗的第一位病人嗎?還是你基本上是在說那時就能上市(launch)?
José E. Almeida - Chairman, CEO and President
José E. Almeida - Chairman, CEO and President
Clinical trial. Clinical trial will be -- first, it's a bit of I would say fourth quarter of 2018, we're going to have our first patient clinical trial. And from that point on, we're going to roll it out as soon as we can in terms of getting the population defined by the agencies in terms of clinical trials. And the launch will be looking at probably towards the end of 2019.
臨床試驗。臨床試驗——首先,我會說大概在2018年第四季,我們會有第一位病人進入臨床試驗。從那之後,我們會在監管機構就臨床試驗所界定的受試人群(population)到位後,盡快推進展開。而上市時間大概會落在2019年底左右。
Lawrence H. Biegelsen - Senior Analyst
Lawrence H. Biegelsen - Senior Analyst
That's very helpful. And then just on M&A, could you talk about M&A pipeline and why we haven't seen more activity besides the Claris deal? And given the change in the deal size that you talked about earlier on this call, have your targets or areas of interest changed or evolved since you last provided update?
這非常有幫助。接著關於併購(M&A),你能談談併購管線,以及為什麼除了Claris這筆交易之外,我們沒有看到更多活動嗎?另外,考量你在本次電話會議較早時提到交易規模的變化,你們的標的或關注領域,是否自上次更新以來有所改變或演進?
José E. Almeida - Chairman, CEO and President
José E. Almeida - Chairman, CEO and President
Larry, this is a very dynamic marketplace and a lot of things happening. We have a relentless focus in inorganic opportunities. But inorganic opportunities is now what will drive our company solely. So we do a very good balance between how much time we spent in looking for new opportunities, how much we spend managing Baxter's current businesses and making sure that all the businesses are performing well. We are every month looking at, at least 10, 12 opportunities. Some fall off for financial reasons. Some of them have changed in dynamics and performance and situations. With the expansion of our reach in terms of size, it brings a bit more opportunity to the table in terms of evaluating. This doesn't mean that we're going to do the deal, but this means that we're going to evaluate. And one thing Baxter is trying to do very well, we're very fast in evaluating the deal, coming to the table, having had significantly our internal capabilities, which are under Andy Kidd, who runs the strategy for us in BD&L, and David Roman, who is in strategy as well here. So these teams have been put together, a significant amount of horsepower. So we are doing everything we can. But the first thing is if it strategically makes sense, it needs to make sense for our shareholders. The money when we look at this, this is not our money, we're just here taking care of the money for our shareholders.
Larry,這是一個非常動態的市場,很多事情正在發生。我們對非有機機會保持不懈的專注。但非有機機會並不是唯一會驅動我們公司的因素。因此,我們在投入多少時間尋找新機會、投入多少時間管理百特目前的業務並確保所有業務表現良好之間,做了非常好的平衡。我們每個月都會檢視至少10到12個機會。有些因財務原因而被排除。有些則因動態、表現與情勢改變而不再適合。隨著我們在規模上的觸及範圍擴大,在評估方面也帶來更多機會。這不代表我們一定會做交易,但代表我們會進行評估。百特努力做得很好的一點是:我們在評估交易、走到談判桌前的速度非常快;我們也大幅強化了內部能力,由負責BD&L策略的Andy Kidd,以及同樣在此負責策略的David Roman領導。因此,這些團隊已經組建完成,具備相當可觀的戰力。所以我們正在盡一切所能。但第一件事是:在策略上是否合理;同時也必須對我們的股東合理。我們在看這些資金時,這不是我們自己的錢;我們只是受託為股東管理資金。
Operator
Operator
And our next question comes from Bob Hopkins of Bank of America.
下一個問題來自美國銀行(Bank of America)的Bob Hopkins。
Robert Adam Hopkins - MD of Equity Research
Robert Adam Hopkins - MD of Equity Research
So I wanted to ask a quick question for Jay and then a follow-up for Joe. So Jay, just to start out, obviously, a lot of people are looking forward to next quarter when you give us an update on the long-range plan. I was just -- in anticipation of that, are there things that you think we should be focusing on in terms of major puts and takes to the long-term plan, things that you'd want to highlight that investors should be considering as we think about the long-term relative to your previous guidance, obviously?
我想先問Jay一個簡短問題,然後再追問Joe。Jay,先從這裡開始,顯然很多人都很期待你們在下個季度更新長期計畫。我只是——在那之前想先請教,你認為我們在長期計畫的主要利多與利空(puts and takes)方面,應該聚焦哪些重點?有沒有你想特別強調、投資人應該在思考長期展望、相對於你們先前指引時納入考量的事項?
James K. Saccaro - CFO and Corporate VP
James K. Saccaro - CFO and Corporate VP
Look, I don't know that we would -- we have items that are new items to point out with respect to our long-term guidance at this stage. The biggest driver, the biggest note I would make is we are certainly ahead of our expectations. And the guidance that we give for this year in 2017 currently sits at $220 million to $228 million. I believe that's above the 2018 guidance we shared in July of last year. So a lot of work, a lot of strong momentum. That's probably the biggest change that we've seen in our overall guidance. In areas like working capital or CapEx, we've also seen some improvements. So those would be a couple of other items that we're hard at work in our long-range financial planning process isolating. Beyond that, there's no major dynamic change. We are excited about some of the portfolio items that Joe highlighted in his comments earlier and some of the work that our teams have done from an R&D standpoint. So that should feature. But again, the biggest impact, those will come a little bit later in the long-range plan.
坦白說,我不確定在這個階段,我們是否會——就長期指引而言,有新的事項需要特別指出。我會強調的最大驅動因素、最重要的一點是:我們確實超前於原先的預期。而我們目前對2017年的年度指引為2.20億至2.28億美元。我認為這高於我們在去年7月所分享的2018年指引。因此,做了很多工作,也有很強的動能。這大概是我們整體指引中看到的最大變化。在營運資金或資本支出(CapEx)等領域,我們也看到一些改善。因此,這些會是我們在長期財務規劃流程中正努力釐清的另外幾個項目。除此之外,沒有重大的動態變化。我們對Joe先前評論中提到的一些投資組合項目,以及我們團隊在研發(R&D)方面所做的一些工作感到振奮。因此,這些應該會成為重點。但再次強調,最大的影響會在長期計畫的稍後部分才會顯現。
Robert Adam Hopkins - MD of Equity Research
Robert Adam Hopkins - MD of Equity Research
Okay. And then for Joe, just on this M&A commentary. I was wondering if you could kind of talk a little bit about your priorities. And 2, I guess 2 specific questions. One, as you consider M&A, would you consider something that's a little bit more of a white space? And then secondly, on the wound management side, I was wondering if you could just talk about that transaction a little bit more and your interest broadly in wound management as a category?
好的。接著給Joe,關於你對併購(M&A)的評論。我想請你談談你們的優先順序。我有兩個具體問題。第一,在考量併購時,你們是否會考慮一些較偏「空白領域」(white space)的機會?第二,在傷口照護(wound management)方面,我想請你再多談一點那筆交易,以及你們對傷口照護作為一個類別的整體興趣?
José E. Almeida - Chairman, CEO and President
José E. Almeida - Chairman, CEO and President
Hi, Bob. we have 4 areas that we consider core growth in our portfolio. It doesn't mean that we don't pay attention or either invest in those other areas, we do when we pay a lot of cash dividends. But Renal is about new therapies and end-to-end care of our patients. Then we have critical care, which is an augmentation of what we already have between acute Renal care as well as our IPS or fluid management business. Then we have the Baxter pharmaceutical business, which is to go into generics and eventually into biosimilars, okay, all injectables. Cyclophosphic molecules and oncolytics, so that's the Baxter pharmaceutical. And then you have advanced surgery, which is to complement our products. So the way we think about this, by defining broader categories within Baxter, allows us to look at spaces that is less singularly focused on the product but more focused in the areas of care. So in process of looking at this, we will stumble in -- at opportunities and encounter opportunities that have a little bit of white space in them. At the moment, we are looking at all the medications to support areas of growth for us, not specifically and exclusively in white space. We're not there yet. We have our venture capital group here at Baxter, where we look at opportunities in white space but those are the venture capital level. So this should give you a bit more color on how we think about deals.
嗨,Bob。我們在投資組合中認為有四個領域是核心成長。這不代表我們不關注或不投資其他領域;我們也會,只是我們也支付大量現金股利。腎臟(Renal)領域著重於新療法以及對病患的端到端照護。接著是重症照護(critical care),這是在我們既有基礎上的強化,涵蓋急性腎臟照護以及我們的IPS或輸液管理業務。再來是百特的製藥業務,目標是進入學名藥,並最終進入生物相似藥(biosimilars),也就是所有注射劑。包括環磷酰胺(cyclophosphamide)分子與腫瘤溶解療法(oncolytics),這些都屬於百特製藥。然後是先進外科(advanced surgery),用來補強我們的產品。因此,我們透過在百特內部定義更廣的類別,使我們能夠看待一些不那麼單一聚焦於產品、而是更聚焦於照護領域的空間。在這樣的檢視過程中,我們會碰到——也會遇到一些帶有「空白領域」特性的機會。目前,我們正在檢視所有能支持我們成長領域的藥物,而不是特別或專門只看空白領域。我們還沒走到那一步。我們在百特也有創投團隊,會去看空白領域的機會,但那屬於創投層級。希望這能讓你更了解我們如何思考交易。
The second in wound management specifically is our natural adjacency of our biosurgery business, which is in the adjunct technology in the OR. There are opportunities such as this one we just acquired so small business that goes nicely into our reps bags. The wound management per se in terms of traditional wound management is specifically is not an area of interest. As I said, we may come across a company that we like overall products, but has that as a small business is a different conversation. But to have us specifically targeting wound management is not something that is in the cards at the moment in time. This has to do with wound closure, which is very adjacent to our hemostat and sealant business.
第二點,特別就傷口照護而言,它是我們生物外科(biosurgery)業務的自然相鄰領域;該業務是在手術室(OR)中的輔助技術。像我們剛收購的這個機會——一家小型企業——很適合放進我們業務代表的產品包裡。至於傳統意義上的傷口照護本身,並不是我們感興趣的領域。如我所說,我們可能會遇到一家我們整體產品很喜歡的公司,而它的傷口照護只是其中一個小型業務,那又是另一種討論。但要我們明確以傷口照護為目標去鎖定,現階段並不在規劃之中。這筆交易與傷口閉合(wound closure)有關,與我們的止血劑(hemostat)與封合劑(sealant)業務非常相鄰。
Operator
Operator
And our next question comes from Danielle Antalffy of Leerink Partners.
下一個問題來自Leerink Partners的Danielle Antalffy。
Danielle Antalffy - Director, Medical Supplies and Devices
Danielle Antalffy - Director, Medical Supplies and Devices
Jay, I wanted to ask you about fiscal '17 guidance and the incremental guidance on EPS beyond the Q1 outperformance. What segments do you expect to drive incremental strength versus prior expectations there?
Jay,我想問你關於2017財年的指引,以及在第一季表現優於預期之外,對每股盈餘(EPS)所提供的增量指引。相較於先前預期,你認為哪些事業部門將帶動額外的強勁表現?
James K. Saccaro - CFO and Corporate VP
James K. Saccaro - CFO and Corporate VP
Sure. So as we look at the updated guidance, the midpoint of the range increases about $0.10. And principally, $0.07 of that has arrived in Q1. We expect another $0.03 related to cyclophosphamide. So really those are the drivers as we look at the margin improvement on a full year basis. The Q1 driver clearly Fluid Systems had a standout quarter. That was an important aspect, along with some SG&A savings that contributed ahead of schedule to drive the $0.07. But really, as we move forward, the big change to guidance relate to cyclo. As we look at other factors like foreign exchange sundry, interest tax and share count, they all net -- essentially net out to 0. So the big drivers are the 2 that I've mentioned.
當然。因此,當我們看更新後的指引時,區間中點大約上調了0.10美元。而其中主要有0.07美元已在第一季實現。我們預期另有0.03美元與環磷醯胺(cyclophosphamide)相關。所以,從全年基礎來看,這些確實就是我們觀察毛利率改善的主要驅動因素。第一季的驅動因素很明確:流體系統(Fluid Systems)表現突出。這是一個重要面向,再加上一些SG&A(銷售、一般及行政)費用節省,較原先時程提前貢獻,推動了這0.07美元。但真正地,隨著我們往前看,指引的最大變動與cyclo相關。至於其他因素,例如外匯雜項、利息、稅負與股數,它們合計——基本上相互抵銷為0。因此主要驅動因素就是我提到的這兩項。
Danielle Antalffy - Director, Medical Supplies and Devices
Danielle Antalffy - Director, Medical Supplies and Devices
Okay, that's helpful. And then just longer term, if we think about Claris and what that brings to the generic injectables business, how does that change the growth profile of that business? That's a market -- a global market that I think is growing in the 9% to 10% range. So curious if you think Claris is something that gets you to within that market growth range, above that market growth range? And then do you feel like generic injectables, Joe, you mentioned augmenting existing businesses. Do you feel like generic injectables is now set with Claris and you'll look elsewhere to augment your businesses?
好的,這很有幫助。接著從更長期來看,如果我們思考Claris以及它為學名注射劑業務帶來的價值,這會如何改變該業務的成長輪廓?我認為那是一個——全球市場,成長率大約在9%到10%的區間。所以想請教你是否認為Claris能讓你們達到該市場成長區間之內,或是高於該市場成長區間?另外,Joe,你提到要強化既有業務。你是否覺得在有了Claris之後,學名注射劑這塊就已經到位,接下來你們會轉向其他領域來強化你們的業務?
José E. Almeida - Chairman, CEO and President
José E. Almeida - Chairman, CEO and President
Danielle, if you look at our long-term objective, it's to be a mid-single-digit growth rate, okay? And the only way to get there in the markets that we are today is to go into a business like the generic injectables, which has a weighted average -- will change the weighted average market growth rate of our company. So I would say that Claris will have an impact slightly in 2018. And then when you go in 2019 and '20, they would bring probably 50 to 100 basis points of incremental growth to the company because not Claris itself but it's everything else that will be attached to Claris. Claris has great manufacturing capabilities. In our integration plans, we already signed to expand a couple of their buildings to put more capability like to our (inaudible) and other things there. So we are looking at that as a platform. So I would say that with comfort, that 50 to 100 basis points in the midterm growth rate is acceptable. We're looking at Brik Eyre and Robert Felicelli to really deliver on those numbers and also to augment our molecule pipeline.
Danielle,如果你看我們的長期目標,是要達到中個位數的成長率,好嗎?而在我們目前所處的市場中,要達到那個目標的唯一方式,就是進入像學名注射劑這樣的業務,它具有加權平均——將會改變我們公司加權平均的市場成長率。所以我會說,Claris在2018年會帶來些微影響。然後到了2019年與2020年,它們可能會為公司帶來約50到100個基點的增量成長;原因不是Claris本身,而是所有將會附著在Claris之上的其他事物。Claris擁有很強的製造能力。在我們的整合計畫中,我們已經簽約要擴建他們其中幾棟建築,以導入更多能力,例如我們的(聽不清)以及其他項目。因此我們把它視為一個平台。所以我可以有把握地說,在中期成長率上增加50到100個基點是可接受的。我們期待Brik Eyre與Robert Felicelli真正交付這些數字,並且也強化我們的分子產品線(molecule pipeline)。
Operator
Operator
And our next question comes from Matt Miksic of UBS.
下一個問題來自瑞銀(UBS)的Matt Miksic。
Matthew Stephan Miksic - Executive Director and Senior Research Analyst
Matthew Stephan Miksic - Executive Director and Senior Research Analyst
So I wanted to follow-up, Joe. I know you've gotten a couple of questions on M&A and strategic thinking on acquisitions. And I just -- I guess one of the questions that we got and we hear in the press particularly following some of the recent deals is sort of this idea of scale or leverage on a platform or leveraging your distribution. And you could say the small -- the wound care, wound closure acquisition you talked about sort of fits that on a smaller scale. But with -- and especially the injectables kind of in place and your ability to sort of continue to add molecules there, you're talking about a larger deal, I guess. To what degree does the growth, the scale, the leverage, the distribution overlap kind of play a role in your thinking? And then I have one follow-up.
Joe,我想追問一下。我知道你已經被問了幾個關於併購(M&A)以及收購策略思維的問題。我只是——我想我們收到的一個問題,以及我們在媒體上聽到的,特別是在近期一些交易之後,是關於規模、平台槓桿,或是利用你們的通路分銷的這種概念。你可以說你提到的那筆較小規模的——傷口照護、傷口閉合的收購,在較小尺度上符合這個概念。但在——尤其是注射劑這塊已經就位,而且你們也能持續在那裡增加分子品項的情況下,你談的是一筆更大的交易,我想。成長、規模、槓桿、通路重疊這些因素,在你們的思考中扮演多大角色?然後我還有一個追問。
José E. Almeida - Chairman, CEO and President
José E. Almeida - Chairman, CEO and President
Matt, you have to think about why -- what are the major prerequisites for something to get into the funnel, and one of them is being within those 4 pillars I mentioned before. The second thing is to make sure there is category leadership and the products that people make and sell. Then once you pass through those broad lenses is about what can Baxter do to be a better owner for that business? And if you look at our contract capability in the U.S. now as comps business growth in the U.S., there's a phenomenal drive doing that. So that is a positive effect. Baxter is a hospital company and we are a supply company. We are in every hospital in this country. So we still have the ability to bring inner systems of distribution as well as how we manage sales and marketing within the regions of the world because we are effective and very efficient in doing it. Above and beyond that, the scale of products and the ability to synergize on them by channel. You have the whole efficiency of cost to maintain the infrastructure. The fewer G&A, which I think now we are in a position to really bring a lot of synergies to the table that about 1.5 year ago, we were not. So that gives me confidence that once -- and if we find the right opportunity for Baxter and our shareholders, we will have the channel synergy as well as the cost synergy. Now remember, we always have this conversation about improving our weighted average market growth rate. And that's the only and sole focus of going into businesses on an inorganic manner. To get businesses that have markets that they serve that will be complementary to ours and the growth will be accretive to ours. So once we get those things on the table, we can make our decisions more clearly.
Matt,你必須思考為什麼——也就是,讓某個標的能進入評估漏斗的主要先決條件是什麼,其中之一是必須落在我先前提到的四大支柱之內。第二件事是要確保在其所製造與銷售的產品上具備品類領導地位。當你通過這些宏觀的檢視之後,接下來就是:Baxter能做什麼,才能成為該業務更好的擁有者?如果你看我們目前在美國的合約能力,作為美國業務成長的比較基準(comps),推動力非常強。所以那是一個正面效應。Baxter是一家醫院公司,而我們是一家供應公司。我們在這個國家的每一家醫院都有佈局。因此我們仍然有能力導入內部的配送系統,以及在全球各區域如何管理銷售與行銷,因為我們在這方面做得有效且非常高效率。除此之外,還有產品規模以及按通路進行協同的能力。你也擁有維持基礎設施的成本效率。更少的G&A(一般及行政)費用;我認為現在我們已經處於一個位置,能夠把很多協同效益帶上桌,而在大約1.5年前我們還做不到。因此這讓我有信心:一旦——如果我們找到對Baxter及股東而言合適的機會,我們將同時具備通路協同以及成本協同。請記得,我們一直在談改善我們的加權平均市場成長率。而這就是以非有機方式進入新業務的唯一且唯一的重點。取得其所服務市場能與我們互補、且其成長能對我們具增益(accretive)的業務。所以當這些條件都具備後,我們就能更清楚地做出決策。
Matthew Stephan Miksic - Executive Director and Senior Research Analyst
Matthew Stephan Miksic - Executive Director and Senior Research Analyst
Now it's very clear. And I have one follow-up on just one of your business lines, the pump business. And I apologize, I've been hopping back and forth between a couple of calls. So if this has been asked, just let me know. But your thoughts on sort of the health of that general business. You've obviously done quite well in that in terms of regaining share. So where should we think about that business going from here? And is there anything else than the product pipeline that we should be looking forward to, to kind of sustain this growth rate that you've been able to put up?
現在非常清楚了。我還有一個追問,關於你們其中一條業務線——幫浦業務。抱歉,我一直在幾通電話之間來回切換。所以如果這已經被問過,請直接告訴我。但我想聽聽你對這個整體業務健康狀況的看法。你們顯然在那方面做得很好,尤其是在重新奪回市占率方面。那麼從現在開始,我們應該如何看待這項業務接下來的走向?除了產品管線之外,還有沒有其他我們應該期待、用以維持你們目前所展現之成長率的因素?
José E. Almeida - Chairman, CEO and President
José E. Almeida - Chairman, CEO and President
Sure. We'll forgive you for flipping calls back and forth (inaudible). So this is a platform for Baxter. Baxter had this product line for decades in several different shapes and form. We are here to stay. We have the SPECTRUM platforms today in the U.S. and Canada, which is doing very, very well. Most importantly is not only the pumps, but also the ability to play the sets. And the sets are what continues to deliver on profitability and revenue growth. We have couple more generations of our SPECTRUM pump coming out in the next couple of years, and then we're going to launch a new global platform that includes different Baxter pumps that were currently in development. For outside the U.S., we have a partnership with a foreign manufacturer where we're going to be augmenting our product lines in Anglo-Saxon-speaking countries. So we have the ability to replace our old platform called COLLEAGUE, which is still being sold outside the U.S. in a few countries with a much more modern. But the beauty about our platform on a global basis is our drug library is second to [NIH] . And having that being retrofitted in any platform, including the one that we are developing with the foreign pharma in the moment is really important. So our teams are working very hard. We have augmented our research and development teams across the globe. We have strong center in the U.S. We have centers now in India. We augmented not only with third-party design houses, but also our own people in our R&D centers in India. So we're ramping up to really make this business a leading business in the industry it competes.
當然。你來回切換電話(聽不清)我們就原諒你了。所以這是一個屬於 Baxter 的平台。Baxter 這條產品線以多種不同的形態與形式已經存在了數十年。我們會長期投入。我們目前在美國與加拿大有 SPECTRUM 平台,表現非常、非常好。最重要的不只是幫浦本身,還包括搭配使用輸注管路組(sets)的能力。而這些管路組正是持續帶來獲利能力與營收成長的關鍵。未來幾年我們還會推出幾代新的 SPECTRUM 幫浦,接著我們將推出一個新的全球平台,涵蓋目前正在開發中的不同 Baxter 幫浦。在美國以外,我們與一家海外製造商合作,將在英語系國家擴充我們的產品線。因此我們有能力以更現代化的平台,取代我們舊的平台 COLLEAGUE;該平台目前仍在美國以外的少數國家銷售。但我們全球平台的優勢在於,我們的藥物資料庫僅次於 [NIH]。而能將其回溯整合(retrofit)到任何平台上,包括我們目前正與海外製藥夥伴共同開發的平台,這點非常重要。因此我們的團隊正非常努力地工作。我們已在全球擴編研發團隊。我們在美國有強大的中心。我們現在在印度也有中心。我們不僅透過第三方設計公司擴充,也在印度的研發中心增補了自有人員。因此我們正在加速推進,真正把這項業務打造為其所競爭產業中的領先業務。
Operator
Operator
And our next question comes from Glenn Novarro of RBC Capital Markets.
下一個問題來自 RBC Capital Markets 的 Glenn Novarro。
Glenn J. Novarro - Analyst
Glenn J. Novarro - Analyst
Joe, I wonder if you can comment on surgical volumes in the first quarter. One of the companies that we cover last week came in with better volumes, and they thought maybe the uncertainty about health care reform may have pulled forward some volumes into the first quarter. And I look at your Fluid Systems, up very strong. So maybe comment on what you saw in terms of volumes. And do you think there was any pull-forward in cases? And then I have a follow-up.
Joe,我想請你評論一下第一季的手術量。我們上週追蹤的一家公司手術量表現更好,他們認為醫療改革的不確定性可能把部分手術量提前拉到第一季。我看你們的 Fluid Systems 表現非常強勁。所以想請你談談你們看到的量的情況。你認為是否有病例提前發生(pull-forward)?然後我還有一個追問。
José E. Almeida - Chairman, CEO and President
José E. Almeida - Chairman, CEO and President
Glenn, I don't think there was any pull-forward. I think our cycle of sales and growth that Jay had explained there, we have to do a lot with replacements of products that we have early this year and also in the last 1.5 years. So we see the U.S. business -- the U.S. supply business as steady, has a low single-digit growth but it is growing. And we don't see at the moment anything that would create major disruption to the system. Clearly, health care reform is up there. They were looking at tax reform and how things are coming along. But I think in businesses like ours, where the significant infrastructure products that are used for day-to-day operation of a hospital or care center or for patient care like our PD business, we see that the market in the U.S. is still a good market. The growth -- intrinsic growth is about 2%, 3%. So we find no disruption in the near term or foreseeable future to that market.
Glenn,我不認為有任何提前拉貨(pull-forward)。我認為正如 Jay 剛才解釋的,我們的銷售與成長週期,很大一部分來自於今年年初以及過去一年半我們產品的汰換需求。因此我們看到美國業務——美國供應業務維持穩定,呈現低個位數成長,但確實在成長。而且目前我們沒有看到任何會對系統造成重大擾動的因素。當然,醫療改革是大家關注的議題。他們也在看稅改以及進展情況。但我認為像我們這樣的業務,提供的是醫院或照護中心日常運作所需的重要基礎設施產品,或是像我們 PD 業務這類用於病患照護的產品,我們看到美國市場仍然是個不錯的市場。成長——內生成長約為 2%、3%。因此我們認為短期或可預見的未來,該市場不會出現任何擾動。
Glenn J. Novarro - Analyst
Glenn J. Novarro - Analyst
And then just as a follow-up, can you talk about your emerging market growth in the quarter? And the reason I'm asking is your international results came in a little bit below our expectations. And I know you've exited some business lines. But I'm just trying to search for why international may have come in a little bit lower. Maybe it's emerging markets. So can you talk about emerging market growth? And has emerging markets growth been meeting your expectation, exceeded expectations or coming in light?
那再追問一下,你能談談本季新興市場的成長嗎?我之所以這麼問,是因為你們的國際業績略低於我們的預期。我知道你們已退出一些業務線。但我想釐清為什麼國際業務可能會低一些。也許是新興市場的因素。所以你能談談新興市場的成長嗎?新興市場的成長是否符合你們預期、超出預期,或是低於預期?
José E. Almeida - Chairman, CEO and President
José E. Almeida - Chairman, CEO and President
Glenn, once you take out the businesses that we exited, which are mostly -- I'm sorry, not mostly, all in emerging markets. So you're talking about India. You're talking about Venezuela. You're talking about Turkey. Our growth was 6%. And in emerging markets, it's 20% to 22% of our overall sales. You have an impressive growth in Latin America, excellent as well as 10%. We had good growth in China, 5%. Remember, we are not in position preferred medical devices in China. We are local manufacturer of fluids in China for PD and some specialty fluids for IV as well as nutrition. So 5% is a good growth in China for those products. Emerging Asia, 5% and East EMEA which is all that Eastern Europe, Middle East and Africa is about 4%. So I'm quite happy with that. We have to exit those businesses because the profitability profile of them were way below what we had set as acceptable for our company. But ex those businesses, we are pretty good there. The issue that we have in international is some parts of Europe, which are underperforming, as I said, we're taking matters to replace management by also to expand product line offerings and clinical trials to get new products in the market there.
Glenn,把我們退出的業務扣除後——這些退出的業務主要是——抱歉,不是主要,而是全部都在新興市場。也就是印度。也包括委內瑞拉。也包括土耳其。我們的成長是 6%。而新興市場約占我們總銷售的 20% 到 22%。拉丁美洲成長令人印象深刻,也很出色,達到 10%。我們在中國有不錯的成長,5%。請記得,我們在中國不是「優先」的醫療器材供應商。我們在中國是 PD 用液體的本地製造商,並生產一些用於 IV 的特殊輸液以及營養產品。因此對這些產品而言,中國 5% 的成長是好的成長。新興亞洲 5%,而東部 EMEA(涵蓋東歐、中東與非洲)約 4%。所以我對此相當滿意。我們必須退出那些業務,因為它們的獲利結構遠低於我們為公司所設定的可接受水準。但扣除那些業務後,我們的表現相當不錯。我們國際業務的問題在於歐洲的某些地區表現不佳;如我所說,我們正在採取措施,包括更換管理團隊,同時擴大產品線供給與臨床試驗,以便在那裡把新產品推向市場。
Operator
Operator
Thank you. And that concludes our question-and-answer session for today. Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for participating.
謝謝。今天的問答環節到此結束。各位女士、先生,Baxter International 今天的電話會議到此結束。感謝各位參與。